The centrally acting non-narcotic antitussive tipepidine produces antidepressant-like effect in the forced swimming test in rats

Behavioural Brain Research

Volumn 205, Issue 1, 2009, Pages 315-318

  Kawaura, Kazuaki ^a   Ogata, Yukino ^a   Inoue, Masako ^a   Honda, Sokichi ^a   Soeda, Fumio ^a   Shirasaki, Tetsuya ^a   Takahama, Kazuo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Antidepressant like effect; Antitussives; Dopamine; Forced swimming test; G protein coupled inwardly rectifying K+ (GIRK) channel; Tipepidine

Indexed keywords

TIPEPIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLIMBING; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; FORCED SWIMMING TEST; IMMOBILIZATION STRESS; LOCOMOTION; MALE; MOTOR COORDINATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LOCOMOTION; MALE; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; RATS; RATS, WISTAR; SWIMMING; TIME FACTORS;

EID: 70349285985     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.07.004     Document Type: Article

References (33)

1. Arai A., Tomiyama M., Kannari K., Kimura T., Suzuki C., Watanabe M., Kawarabayashi T., Shen H., and Shoji M. Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter. Synapse 62 (2008) 632-635
2. Cassano P., Lattanzi L., Soldani F., Navari S., Battistini G., Gemignani A., and Cassano G.B. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 20 (2004) 131-138
3. Craviso G.L., and Musacchio J.M. High-affinity dextromethorphan binding sites in guinea pig brain. II-Competition experiments. Mol Pharmacol 23 (1983) 629-640
4. Detke M.J., and Lucki I. Detection of serotonergic antidepressant in the rat forced swimming test: the effects of water depth. Behav Brain Res 73 (1996) 43-46
5. Detke M.J., Rikels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121 (1995) 66-72
6. De Vry J., Schreiber R., Melon C., Dalmus M., and Jentzsch K.R. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropsychopharmacol 14 (2004) 487-495
7. Dunhan N.W., and Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc 46 (1957) 208-209
8. Hemby S.E., Lucki I., Gatto G., Singh A., Thornley C., Matasi J., Kong N., Smith J.E., Davies M., and Dworkin S.I. Potential antidepressant effects of novel tropane compounds, selective for serotonin or dopamine transporters. J Pharmacol Exp Ther 282 (1997) 727-733
9. Higuchi H., Kamata M., Sugawara Y., and Yoshida K. Remarkable effect of selegiline (l-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report. Clin Neuropharmacol 28 (2005) 191-192
10. Inoue M., Shirasaki T., Soeda F., and Takahama K. Effect of cloperastine on 5-HT level in rat prefrontal cortex: an in vivo microdialysis study. J Pharmacol Sci 106 Suppl. 1 (2008) 187P
11. Inoue M., Kawaura K., Ogata Y., Honda S., Shirasaki T., Soeda F., and Takahama K. Cloperastine remarkably increased the level of DA compared to the level of 5-HT in the brain. Folia Pharmacol Japon 133 (2009) 33P (in Japanese)
12. Inoue M., Soeda F., Shirasaki T., and Takahama K. Cloperastine increases dopamine level in the nucleus accumbens or rats. J Pharmacol Sci 109 Suppl. 1 (2009) 276P
13. Kamei J., Mori T., Igarashi H., and Kasuya Y. Serotonin release in the nucleus of the solitary tract and its modulation by antitussive drugs. Res Commun Chem Pathol Pharmacol 76 (1992) 371-374
14. Kase Y, Yuizono T. Pharmacology of cough reflex (The 13th report); Studies on a novel synthetic non-narcotic antitussive. Folia Pharmacol Japon 1960;56:74ξ (in Japanese).
15. Kellie J.W., Crystal C.W., and Eric L.B. Serotonin transporter: implication for antidepressant drug development. AAPS J 7 (2005) 421-433
16. Kihara T., and Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272 (1995) 177-183
17. + channels by various antidepressant drugs. Neuropsychopharmacology 29 (2004) 1841-1851
18. Mancinelli A., Borsini F., d'Aranno V., Lecci A., and Meli A. Cholinergic drug effects on antidepressant-induced behavior in the forced swimming test. Eur J Pharmacol 158 (1988) 199-205
19. Nemeroff C.B., Entsuah R., Willard L.B., Demitrack M.A., and Thase M.E. Comprehensive pooled analysis of remission data: venlafaxine versus SSRIs (COMPARE). Biol Psychiatry 63 (2003) 424-434
20. Nguyen E.C., McCracken K.A., Liu Y., Pouw B., and Matsumoto R.R. Involvement of sigma(σ) receptors in the acute actions of metamphetamine: receptor binding and behavioral studies. Neuropharmacology 49 (2005) 638-645
21. North R.A. Drug receptors and the inhibition of nerve cells. Br J Pharmacol 98 (1989) 13-28
22. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 5604 (1977) 730-732
23. Rénéric J.P., and Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology 136 (1998) 190-197
24. Rudolph R.L. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 415 (2002) 24-30
25. Shimazu S., Minami A., Kusumoto H., and Yoneda F. Antidepressant-like effects of selegiline in the Forced swim test. Eur Neuropsychopharmacol 15 (2005) 563-571
26. + channel GIRK2. Proc Natl Acad Sci USA 94 (1997) 923-927
27. Slatterly D.A., Hudson A.L., and Nutt D.J. Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol 18 (2004) 1-21
28. Smith D., Dempster C., Glanvile J., Freemantle N., and Anderson I. Efficacy and tolerability of venlafaxine compare with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180 (2002) 396-404
29. Stahl S.M., Entsuah R., and Rudolph R.L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 52 (2002) 1166-1174
30. Takahama K., Shirasaki T., and Soeda F. Central mechanisms III: neuronal mechanisms of action centrally acting antitussives using electrophysiological and neurochemical study approaches. In: Chung K.F., and Widdicombe J. (Eds). Handbook of experimental pharmacology; pharmacology and therapeutics of cough vol. 187 (2009), Springer-Verlag, Berlin 219-240
31. Thase ME, Entsuah R, Sloan DM, Nemeroff CB. Meta-analysis of randomized controlled trials comparing venlafaxine and SSRIs: the evidence revisited. Presented at the annual meeting of the American Psychiatric Association, Atlanta, GA; 2005.
32. Thase M.E., Entsuah A.R., and Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178 (2001) 234-441
33. Wickman K., Nemec J., Gendler S.J., and Clapham D.E. Abnormal heart rate regulation in GIRK4 knock out mice. Neuron 20 (1998) 103-114